Shares in Danish drug maker Novo Nordisk (NOVO B), known for its blockbuster drugs Ozempic and Wegovy, fell as much as 28% on Friday after it released the results of a clinical trial for the experimental obesity drug CagriSema.
CagriSema helped patients lose an average of 22.7% of their body weight in a late-stage trial, missing the goal for an average of 25% weight loss. The result was only marginally better than the average weight loss of 20.2% of Zepbound, a rival treatment from Eli Lilly LLY. Eli Lilly edged 10% higher in the US premarket.
The phase 3 study included around 3,400 people with a BMI above 30 or BMI above 27 combined with some weight-related morbidity.
Analysts at Berenberg concluded in a survey in late September that if CagriSema is equivalent to Zepbound’s figure of 20% average weight loss, the share price reaction would be hard to predict, with a share price reaction in this scenario ranging from -20% to +5%. The market reacted even stronger initially, but recovered the fall slightly to -20% about an hour after the news.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.
SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk
